chevron_leftBack
As of 24 June 2026, Suzhou Ribo Life Science Co., Ltd. has a market cap of $1.33B USD, ranking #9120 globally and #2445 in China.
It ranks #781 in the Healthcare sector, and #37 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$1.33BUSD
10.44B HKD
Enterprise Value
$1.37BUSD
10.73B HKD
Revenue (TTM)
$21.08MUSD
165.26M HKD
EBITDA (TTM)
-$34.32MUSD
-268.95M HKD
Net Income (TTM)
-$39.47MUSD
-309.43M HKD
EBITDA Margin
-163%
Profit Margin
-187%
PS Ratio
63.2
PB Ratio
350.3
Company Profile
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.5% | -7.6% | 4.5% | -18% | -33% | -33% |
Upcoming Earnings
Earnings Date
Fri, Jun 26
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
6938
ISIN: CNE100007DS6
Shares Out.:
Shares Outstanding:
170.555M1
Shares Float:
63.213M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
60.90 HKD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Suzhou Ribo Life Science Co., Ltd.
Suzhou Ribo Life Science Co., Ltd. researches and develops small nucleic acid drugs for treating cardiovascular, metabolic, renal, liver, and other diseases. It develops RBD4059 for treating thrombotic diseases; RBD5044 for treating hypertrigly ceridemia; RBD7022 for treating Hypercho lesterolemia; RBD1016 for treating CHB and CHD that are in Phase II clinical trials. The company also develops RBD7007 and RBD2080 for treating renal diseases; and RBD1119 for treating thrombotic diseases, which are in Phase I clinical trials. In addition, it develops SR122 for treating dyslipidemia; RBD3103 for treating renal diseases; and RBD8088 for treating glioma that are in preclinical trials. The company was founded in 2007 and is based in Kunshan, China.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SHE: 002001
|
$15.84B
1K%
107.34B CNY
|
16.0
|
|
SHE: 002653
|
$9.09B
583%
61.6B CNY
|
80.6
|
|
SHE: 000423
|
$5.21B
292%
35.33B CNY
|
20.0
|
|
SHE: 002603
|
$4.2B
216%
28.47B CNY
|
20.8
|
|
SHE: 000623
|
$3.27B
145%
22.12B CNY
|
8.1
|
|
|
$2.74B
106%
18.55B CNY
|
11.5
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
TLV: TEVA
|
$36.66B
3K%
108.92B ILS
|
24.2
|
|
NASDAQ: RVMD
|
$29.56B
2K%
|
-
|
|
NSE: CIPLA
|
$11.25B
745%
1.06T INR
|
23.4
|
|
NSE: LUPIN
|
$11.14B
736%
1.05T INR
|
22.7
|
|
EPA: ABVX
|
$8.64B
549%
7.57B EUR
|
-
|
|
NSE: AUROPHARMA
|
$8.53B
541%
807.02B INR
|
23.1
|
chevron_leftBack